TY - JOUR
T1 - An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients
AU - The NeuroLINCS Consortium
AU - NYGC ALS Consortium
AU - Phatnani, Hemali
AU - Kwan, Justin
AU - Sareen, Dhruv
AU - Broach, James R.
AU - Simmons, Zachary
AU - Arcila-Londono, Ximena
AU - Lee, Edward B.
AU - Van Deerlin, Vivianna M.
AU - Shneider, Neil A.
AU - Fraenkel, Ernest
AU - Ostrow, Lyle W.
AU - Baas, Frank
AU - Zaitlen, Noah
AU - Berry, James D.
AU - Malaspina, Andrea
AU - Fratta, Pietro
AU - Cox, Gregory A.
AU - Thompson, Leslie M.
AU - Finkbeiner, Steve
AU - Dardiotis, Efthimios
AU - Miller, Timothy M.
AU - Chandran, Siddharthan
AU - Pal, Suvankar
AU - Hornstein, Eran
AU - MacGowan, Daniel J.
AU - Heiman-Patterson, Terry
AU - Hammell, Molly G.
AU - Patsopoulos, Nikolaos A.
AU - Butovsky, Oleg
AU - Dubnau, Joshua
AU - Nath, Avindra
AU - Bowser, Robert
AU - Harms, Matt
AU - Poss, Mary
AU - Phillips-Cremins, Jennifer
AU - Crary, John
AU - Atassi, Nazem
AU - Lange, Dale J.
AU - Adams, Darius J.
AU - Stefanis, Leonidas
AU - Gotkine, Marc
AU - Baloh, Robert H.
AU - Babu, Suma
AU - Raj, Towfique
AU - Paganoni, Sabrina
AU - Shalem, Ophir
AU - Smith, Colin
AU - Zhang, Bin
AU - Harris, Brent
AU - Broce, Iris
N1 - Funding Information:
We thank the patients with ALS and their families for their essential contributions to this research. We also thank Dr. Shana Svendsen for editorial assistance. We also acknowledge and thank the Target ALS Postmortem Tissue Core for their contribution of samples and data. Funding: Primary support for this work was from NIH U54 NS091046 NeuroLINCS center (S.F., E.F., J.D.R., C.N.S., J.E.V.E., L.M.T.). Additional support was provided by NIH NS089076 (L.M.T, E.F), NS085207 , NS094239 , Fidelity Bioscience (J.D.R), The Robert Packard Center for ALS Research at Johns Hopkins , Answer ALS Project . The whole-genome analysis was funded by The ALS Association (ALSA) and conducted at the New York Genome Center . The sequencing activities at NYGC were supported by ALSA and The Tow Foundation . This work was made possible, in part, through access to the Genomic High Throughput Facility Shared Resource of the Cancer Center Support Grant (CA-62203) at the University of California , Irvine.
Funding Information:
We thank the patients with ALS and their families for their essential contributions to this research. We also thank Dr. Shana Svendsen for editorial assistance. We also acknowledge and thank the Target ALS Postmortem Tissue Core for their contribution of samples and data. Funding: Primary support for this work was from NIH U54 NS091046 NeuroLINCS center (S.F. E.F. J.D.R. C.N.S. J.E.V.E. L.M.T.). Additional support was provided by NIH NS089076 (L.M.T, E.F), NS085207, NS094239, Fidelity Bioscience (J.D.R), The Robert Packard Center for ALS Research at Johns Hopkins, Answer ALS Project. The whole-genome analysis was funded by The ALS Association (ALSA) and conducted at the New York Genome Center. The sequencing activities at NYGC were supported by ALSA and The Tow Foundation. This work was made possible, in part, through access to the Genomic High Throughput Facility Shared Resource of the Cancer Center Support Grant (CA-62203) at the University of California, Irvine. Designed the experiments: D.S. C.N.S. R.G.L. L.M.T. V.D. J.E.V.E. P.M. M.A. J.L. E.F. J.K. S.F. A.N.C. J.G.D. T.E.L. J.D.R.; cell lines: L.O. E.G. L.P. D.S.; generated iPSC lines in study: B.M. H.T. M.G.B. B.S.; iPSC culture and neuronal differentiation, carried out experiments: B.M. H.T. M.G.B. B.S.; differentiation: R.G.L. J.S.; RNA-Seq: V.D. J.E.V.E. P.M.; proteomics: M.A. B.T.W.; ATAC-seq, analyzed the data: R.G.L. J.W. M.C. L.M.T. V.D. J.E.V.E. P.M. M.A. B.T.W. J.L. R.E.-C. A.L. K.S. N.L.P.-M. D.R. C.N.S. J.A.K. L.L. S.W. S.F.; wrote the manuscript: D.S. C.N.S. R.G.L. J.W. L.M.T. C.D. J.E.V.E. J.L. E.F. A.N.C. J.D.R. J.A.K. S.F.; project leadership and management: S.F. E.F. J.D.R. D.S. C.N.S. J.E.V.E. L.M.T. L.O. T.T. Project leadership: Steven Finkbeiner, Ernest Fraenkel, Jeffrey D. Rothstein, Dhruv Sareen, Jennifer E. Van Eyk, Clive N. Svendsen, and Leslie M. Thompson. iPSC production: Loren Ornelas, Emilda Gomez, Lindsay Panther, Clive N. Svendsen, and Dhruv Sareen. iPSC differentiation and distribution: Aaron Frank, Susan Lei, Berhan Mandefro, Hannah Trost, Maria G. Banuelos, Brandon Shelley, Dhruv Sareen, and Clive N. Svendsen. Whole-genome analysis: Julia A. Kaye, Leandro Lima, Stacia Wyman, and Steven Finkbeiner. RNA-Seq: Ryan G. Lim, Jie Wu, Jennifer Stocksdale, Malcolm Casale, and Leslie M. Thompson. Proteomics: Victoria Dardov, Andrea Matlock, Vidya Venkatraman, Ronald Holewenski, Jennifer E. Van Eyk.7? Epigenomics: Pamela Milani, Miriam Adam, Brook T. Wassie, and Ernest Fraenkel. Drosophila validation screen: Andrew Cheng, Alyssa N. Coyne, J. Gavin Daigle, Johnny Li, Stephanie Yang, Veerle Cox, Mark Wilhelm, Jeffrey D. Rothstein, and Thomas E. Lloyd. DPR and nuclear pore analysis: Alyssa N. Coyne, Lindsey Hayes, Jacqueline Pham, Jeffrey D. Rothstein. Integrative analysis and computational modeling: Jonathan Li, Renan Escalante-Chong, Alex Lenail, Karen Sachs, Ryan G. Lim, Julia Kaye, Natasha Leanna Patel-Murray, Divya Ramamoorthy, Steven Finkbeiner, Leslie M. Thompson, and Ernest Fraenkel. Project management: Terri G. Thompson. The authors declare no competing interests.
Publisher Copyright:
© 2021 The Authors
PY - 2021/11/19
Y1 - 2021/11/19
N2 - Neurodegenerative diseases are challenging for systems biology because of the lack of reliable animal models or patient samples at early disease stages. Induced pluripotent stem cells (iPSCs) could address these challenges. We investigated DNA, RNA, epigenetics, and proteins in iPSC-derived motor neurons from patients with ALS carrying hexanucleotide expansions in C9ORF72. Using integrative computational methods combining all omics datasets, we identified novel and known dysregulated pathways. We used a C9ORF72 Drosophila model to distinguish pathways contributing to disease phenotypes from compensatory ones and confirmed alterations in some pathways in postmortem spinal cord tissue of patients with ALS. A different differentiation protocol was used to derive a separate set of C9ORF72 and control motor neurons. Many individual -omics differed by protocol, but some core dysregulated pathways were consistent. This strategy of analyzing patient-specific neurons provides disease-related outcomes with small numbers of heterogeneous lines and reduces variation from single-omics to elucidate network-based signatures.
AB - Neurodegenerative diseases are challenging for systems biology because of the lack of reliable animal models or patient samples at early disease stages. Induced pluripotent stem cells (iPSCs) could address these challenges. We investigated DNA, RNA, epigenetics, and proteins in iPSC-derived motor neurons from patients with ALS carrying hexanucleotide expansions in C9ORF72. Using integrative computational methods combining all omics datasets, we identified novel and known dysregulated pathways. We used a C9ORF72 Drosophila model to distinguish pathways contributing to disease phenotypes from compensatory ones and confirmed alterations in some pathways in postmortem spinal cord tissue of patients with ALS. A different differentiation protocol was used to derive a separate set of C9ORF72 and control motor neurons. Many individual -omics differed by protocol, but some core dysregulated pathways were consistent. This strategy of analyzing patient-specific neurons provides disease-related outcomes with small numbers of heterogeneous lines and reduces variation from single-omics to elucidate network-based signatures.
UR - http://www.scopus.com/inward/record.url?scp=85123258016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123258016&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2021.103221
DO - 10.1016/j.isci.2021.103221
M3 - Article
C2 - 34746695
AN - SCOPUS:85123258016
SN - 2589-0042
VL - 24
JO - iScience
JF - iScience
IS - 11
M1 - 103221
ER -